Difference between revisions of "Citalopram-agomelatine"

From Psychiatrienet
Jump to: navigation, search
Line 11: Line 11:
 
* '''Day 8:''' only continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day.  
 
* '''Day 8:''' only continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day.  
 
<ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref>
 
<ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref>
 +
 +
|info=
 +
{{review}}
 
}}
 
}}

Revision as of 09:04, 21 October 2015

Citalopram
Type Antidepressant
Group SSRI
links
ATC-code N06AB04
Medscape Citalopram
PubChem 2771
PubMed Citalopram
Kompas (Dutch) citalopram
Wikipedia citalopram
Agomelatine
Type Antidepressant
Group other
links
ATC-code N06AX22
EMEA valdoxan
PubChem 82148
PubMed Agomelatine
Kompas (Dutch) Agomelatine
Wikipedia Agomelatine

Switch medication from citalopram to agomelatine.

Nietinrijdenbord.png Stop citalopram
  • Before day 1: gradually reduce dosage of citalopram to a maximum of 40 mg/day.
  • Day 1: reduce dosage of citalopram to 20 mg/day.
  • Day 8: stop administration of citalopram.
Eenrichtingbord.png Start agomelatine
  • Day 1: simultaneously start administration of agomelatine in a dosage of 25 mg/day.
  • Day 8: only continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day.

[1]

Infobord.png More information
  • This switch is currently being reviewed.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.